Literature DB >> 4130307

A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea.

D L McLellan, R J Chalmers, R H Johnson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4130307     DOI: 10.1016/s0140-6736(74)92338-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  18 in total

Review 1.  Chorea and related disorders.

Authors:  R Bhidayasiri; D D Truong
Journal:  Postgrad Med J       Date:  2004-09       Impact factor: 2.401

2.  Biochemical mechanisms and management of choreiform movement disorders.

Authors:  L de Silva
Journal:  Drugs       Date:  1977-10       Impact factor: 9.546

3.  Tetrabenazine: for chorea associated with Huntington's disease.

Authors:  Lesley J Scott
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

4.  Ropinirole versus placebo in primary restless legs syndrome.

Authors:  John C Morgan; Kapil D Sethi
Journal:  Curr Neurol Neurosci Rep       Date:  2006-07       Impact factor: 5.081

5.  Letter: Low-dosage treatment with tetrabenazine.

Authors:  R Schneider; A P Buchan; T A Couston
Journal:  Br Med J       Date:  1976-05-15

6.  An examination of the action of tetrabenazine on peripheral noradrenergic neurones [proceedings].

Authors:  D R Tomlinson
Journal:  Br J Pharmacol       Date:  1977-06       Impact factor: 8.739

7.  Tetrabenazine in Sydenham's chorea.

Authors:  C H Hawkes; C H Nourse
Journal:  Br Med J       Date:  1977-05-28

Review 8.  Drug discovery and development for rare genetic disorders.

Authors:  Wei Sun; Wei Zheng; Anton Simeonov
Journal:  Am J Med Genet A       Date:  2017-07-21       Impact factor: 2.802

9.  The mode of action of tetrabenazine on peripheral noradrenergic nerves.

Authors:  D R Tomlinson
Journal:  Br J Pharmacol       Date:  1977-11       Impact factor: 8.739

10.  Tetrabenazine in the treatment of Huntington's disease.

Authors:  Diana Paleacu
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.